<DOC>
	<DOCNO>NCT02157558</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state telotristat ethyl pharmacokinetics ( PK ) single-dose fexofenadine healthy subject .</brief_summary>
	<brief_title>An Open-Label Drug-Drug Interaction Study Telotristat Etiprate Fexofenadine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Healthy adult subject age ≥18 ≤55 year age screen Body mass index ≥18.0 ≤32.0 kg/m^2 Acceptable vital sign Screening : Systolic blood pressure = 90140 mm Hg , Diastolic blood pressure = 5090 mm Hg , Heart rate = 40100 beat per minute Willingness adhere restriction outline protocol Able comprehend sign Informed Consent Form Presence clinically significant physical , laboratory , ECG finding may interfere study opinion Investigator Use medication , herbal tea , energy drink , herbal product , supplement within 14 day Day 1 Receipt investigational agent study drug within 30 day 5 halflives prior Screening Receipt protein antibodybased therapeutic agent within 3 month Screening Prior exposure telotristat etiprate Use tobacco , smoke cessation product , nicotine product within 3 month prior Screening History major surgery within 6 month prior Screening History GI surgery may induce malabsorption History serious adverse reaction hypersensitivity component fexofenadine History renal disease , significantly abnormal glomerular filtration rate ( &lt; 90 mL/min calculate use CockcroftGault equation ) Screening History hepatic disease , significantly abnormal liver function test Screening History clinically significant psychiatric , renal , hepatic , pancreatic , cardiovascular , neurological , endocrinologic , hematological , GI abnormality History active infection within 14 day prior first dose History alcohol substance abuse within 2 year prior Screening Positive hepatitis panel ( include hepatitis B surface antigen hepatitis C virus antibody ) positive human immunodeficiency virus antibody screen Concurrent condition could interfere safety and/or tolerability measurement Donation loss &gt; 500 mL blood blood product within 3 month prior Screening Women breastfeed plan become pregnant study Positive serum pregnancy test ( female ) Positive urine screen select drug abuse cotinine Consumption alcohol within 48 hour prior study start Consumption caffeine and/or xanthinecontaining product within 72 hour study start Consumption grapefruit , Seville oranges , grapefruit Seville orangecontaining product within 72 hour prior study start Unable unwilling communicate cooperate Investigator reason Use drug substance know substrate , inducer , inhibitor CYP3A4 within 30 day prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>